PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available
The final project plan of the relative effectiveness of ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)' is now available for access. The final assessment report will be published on 12th March, 2020. Below is the documentation
OTCA22 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Point-of-care Tests (POCT): D-Dimer and Troponin' are now available for access. Troponin and D-dimer point of care tests can be used to aid the diagnosis of patients with
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access the final project plan at the following link: PTJA06 Final Project Plan
OTCA17 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)' are now available for access. The present assessment addressed
OTCA23 Final Project Plan and related documents now available
EUnetHTA is pleased to announce that the final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA23 "Biodegradable rectum spacers to reduce toxicity for prostate cancer'' are now available for access. The final assessment report
PTJA08 – “Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity” project plan now available.
The Final Project Plan of the assessment on siponimod is now available. The final assessment report will be published on 13th February, 2020. Please access the Final Project Plan at the following link: PTJA08 Final Project Plan
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the
OTCA18 Final Assessment Report is now available.
The final assessment report and related documents concerning OTCA18, 'regional hyperthermia for high-risk soft tissue sarcoma treatment', are now available. The assessed technology is regional hyperthermia added to conventional therapies to treat high-risk soft tissue sarcoma. The objective of this rapid
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have